| Title |
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2017
|
| DOI | 10.2147/dddt.s122249 |
| Pubmed ID | |
| Authors |
Alberto Gajofatto |
| Abstract |
Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate (S1P) modulator family, which has putative neuroprotective properties and well-characterized immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly induced by S1P3 receptor activation, such as bradycardia and vasoconstriction. In addition, S1P1 and S1P5 receptors are expressed by neurons and glia and could mediate a possible neuroprotective effect of the drug. A Phase II clinical trial of siponimod for RR MS showed a significant effect of the active drug compared to placebo on reducing gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) after 3 months of treatment. In a recently completed Phase III trial, treatment with siponimod was associated with a significant reduction in disability progression in secondary progressive (SP) MS patients compared to placebo. In this article, current evidence supporting siponimod efficacy for SP MS is reviewed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| United Kingdom | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 15% |
| Student > Bachelor | 11 | 15% |
| Researcher | 10 | 14% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 11 | 15% |
| Unknown | 16 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 25% |
| Neuroscience | 10 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 6% |
| Other | 9 | 13% |
| Unknown | 19 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2020.
All research outputs
#7,780,614
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#525
of 2,268 outputs
Outputs of similar age
#118,347
of 340,752 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 45 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.